# This Prostate Cancer Drug Works. Investors Think It Has the Wrong Partner.

- slug: this-prostate-cancer-drug-works-investors-think-it-has-the-wrong-partner
- date: 2026-04-02
- category: Biotech & Life Sciences

The 84% five-month rPFS looks encouraging until you notice the data comes from just 18 patients, the comparator arm is darolutamide rather than a stronger AR inhibitor, and Wall Street sold off 27% anyway.

---